Aggrenox End-Payors Want $18M Atty Fees In $54M Deal
Law360 (April 13, 2018, 8:20 PM EDT) -- Indirect buyers of Aggrenox told a Connecticut federal judge Friday that attorneys who represented the putative class alleging that Teva Pharmaceutical and Boehringer Ingelheim blocked generic alternatives to the stroke-prevention drug...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
